News stories about Genocea Biosciences (NASDAQ:GNCA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genocea Biosciences earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.9588837941676 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Running on Empty or is Genocea Biosciences Inc (GNCA) Refueling? – Stock Press Daily (stockpressdaily.com)
- Genocea Biosciences Inc (GNCA) Ichimoku Levels Point to Negative Stock Momentum – Evergreen Caller (evergreencaller.com)
- Analysts Anticipate Genocea Biosciences, Inc. (GNCA) Will Post Earnings of -$0.46 Per Share (americanbankingnews.com)
- Genocea Biosciences, Inc. (NASDAQ:GNCA) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Consensus score reveals Buy position in Healthcare Stock: Genocea Biosciences, Inc. (GNCA) ,Matinas BioPharma … – Street Observer (press release) (streetobserver.com)
Shares of Genocea Biosciences (NASDAQ GNCA) traded down 1.40% during trading on Tuesday, reaching $4.93. The company had a trading volume of 115,369 shares. The firm has a 50-day moving average of $5.32 and a 200 day moving average of $5.50. The firm’s market capitalization is $140.51 million. Genocea Biosciences has a 1-year low of $3.28 and a 1-year high of $7.29.
Several analysts have recently commented on the company. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, June 6th. Cowen and Company reiterated an “outperform” rating and set a $40.00 price objective on shares of Genocea Biosciences in a report on Tuesday, July 25th. Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price objective (up previously from $17.00) on shares of Genocea Biosciences in a report on Tuesday, July 25th. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Finally, Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $16.52.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/08/08/genocea-biosciences-nasdaqgnca-given-news-sentiment-score-of-0-16.html.
In related news, CFO Jonathan Poole sold 45,000 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the transaction, the chief financial officer now owns 84,247 shares in the company, valued at $505,482. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 6.70% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.